Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Brenner

Showing results (251-260 of 298) with videos related to

Pageof 30
Sort By:
Nature Communications|March 31, 2019
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver diseaseCyrielle Caussy, Anupriya Tripathi, Greg Humphrey, et al.
Journal of Clinical Gastroenterology|October 9, 2015
Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus OpinionMartin H Floch, W Allan Walker, Mary Ellen Sanders, et al.
The Journal of Cell Biology|September 11, 2013
M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathwayDaniel H Madsen, Daniel Leonard, Andrius Masedunskas, et al.
The Journal of Clinical Investigation|June 18, 2014
Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosisThomas Moore-Morris, Nuno Guimarães-Camboa, Indroneal Banerjee, et al.
Science Translational Medicine|September 11, 2024
HIF-2α drives hepatic Kupffer cell death and proinflammatory recruited macrophage activation in nonalcoholic steatohepatitisIshtiaq Jeelani, Jae-Su Moon, Flavia Franco da Cunha, et al.
Hepatology (Baltimore, Md.)|October 6, 2016
Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and bloodMartin L Decaris, Kelvin W Li, Claire L Emson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2021
Immunotherapy-based targeting of MSLN<sup>+</sup> activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosisTakahiro Nishio, Yukinori Koyama, Xiao Liu, et al.
Journal of Clinical Gastroenterology|February 19, 2005
Information assimilation and distribution challenges and goals for real and virtual journalsIrvin M Modlin, Guido Adler, Kathey Alexander, et al.
Hepatology (Baltimore, Md.)|January 2, 2010
Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in ratsMontserrat Moreno, Teresa Gonzalo, Robbert J Kok, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2024
Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2Souradipta Ganguly, Sara Brin Rosenthal, Kei Ishizuka, et al.
Pageof 30

Showing results (251-260 of 298) with videos related to

Sort By:
Pageof 30
Nature Communications|March 31, 2019
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver diseaseCyrielle Caussy, Anupriya Tripathi, Greg Humphrey, et al.
Journal of Clinical Gastroenterology|October 9, 2015
Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus OpinionMartin H Floch, W Allan Walker, Mary Ellen Sanders, et al.
The Journal of Cell Biology|September 11, 2013
M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathwayDaniel H Madsen, Daniel Leonard, Andrius Masedunskas, et al.
The Journal of Clinical Investigation|June 18, 2014
Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosisThomas Moore-Morris, Nuno Guimarães-Camboa, Indroneal Banerjee, et al.
Science Translational Medicine|September 11, 2024
HIF-2α drives hepatic Kupffer cell death and proinflammatory recruited macrophage activation in nonalcoholic steatohepatitisIshtiaq Jeelani, Jae-Su Moon, Flavia Franco da Cunha, et al.
Hepatology (Baltimore, Md.)|October 6, 2016
Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and bloodMartin L Decaris, Kelvin W Li, Claire L Emson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2021
Immunotherapy-based targeting of MSLN<sup>+</sup> activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosisTakahiro Nishio, Yukinori Koyama, Xiao Liu, et al.
Journal of Clinical Gastroenterology|February 19, 2005
Information assimilation and distribution challenges and goals for real and virtual journalsIrvin M Modlin, Guido Adler, Kathey Alexander, et al.
Hepatology (Baltimore, Md.)|January 2, 2010
Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in ratsMontserrat Moreno, Teresa Gonzalo, Robbert J Kok, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2024
Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2Souradipta Ganguly, Sara Brin Rosenthal, Kei Ishizuka, et al.
Pageof 30